PolyPid Ltd. (PYPD) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Polypid Ltd..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.937 Greetings and welcome to Polypeed's second quarter 2025 00:00:04.937 -- 00:00:10.844 conference call. At this time, participants are in a listen-only mode. 00:00:10.844 -- 00:00:16.130 As a reminder, this call is recorded. And I would now like to introduce your host 00:00:16.130 -- 00:00:21.196 for today's conference, Yuda Liebler from Arts Capital Market. 00:00:21.196 -- 00:00:22.718 Mr. Liebler, you may begin. 00:00:22.718 -- 00:00:24.718 Thank 00:00:25.702 -- 00:00:30.625 you all for participating in Polypeed's second quarter 2025 earnings conference call. 00:00:30.625 -- 00:00:35.109 Joining me on the call today will be Dikla Chachkis-Axelbrod, Chief Executive Officer 00:00:35.109 -- 00:00:40.774 of PolyPID, Johnny Misalawin, PolyPID's Chief Financial Officer, and Ori Warschowski, 00:00:40.774 -- 00:00:46.179 Chief Operating Officer, U.S. of PolyPID. Earlier today, PolyPID released its financial 00:00:46.179 -- 00:00:49.482 results for the three months ended June 30th, 2025. 00:00:49.482 -- 00:00:53.226 A copy of the press release is available in the Investors section on the company's website, 00:00:53.226 -- 00:00:55.986 available at www.polypid.com. 00:00:56.909 -- 00:01:00.595 I'd like to remind you that on this call, management will make forward-looking statements 00:01:00.595 -- 00:01:03.238 within the meaning of the federal securities law. 00:01:03.238 -- 00:01:06.843 For example, management is making forward-looking statements when it discusses DPLEX 00:01:06.843 -- 00:01:11.448 100's potential benefits, including its potential to address a significant unmet medical 00:01:11.448 -- 00:01:15.733 need and to substantially reduce the burden of surgical site infections, improve patient 00:01:15.733 -- 00:01:18.637 outcomes, ...